XImmune is developing new effective treatments based on unique properties of new classes of endogenous host defense peptides discovered to display potent immune-modulating and anti-inflammatory properties. XImmune's proprietary peptides have been shown to have unique immune-modulatory properties, and exert antimicrobial as well as anti-endotoxin and anti-coagulative effects. The goal is to develop these findings into effective treatments for severe inflammatory disorders where no efficient cure exists today.
| Website | http://www.ximmune.com |
| Revenue | $3 million |
| Employees | View employees |
| Founded | 2009 |
| Industry | Biotechnology Research, Drug Discovery, Pharmaceuticals |
| Competitors | Johnson & Johnson, Roche, Pfizer, Sanofi, GSK, AstraZeneca, Regeneron, Moderna Therapeutics, Novavax, Lilly India +50 more (view full list) |
Looking for a particular XImmune AB employee's phone or email?
XImmune AB Questions
The XImmune AB annual revenue was $3 million in 2026.
XImmune AB is based in Madrid, Madrid.
Related Companies
